In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report), with a price target of $61.00. The company’s shares closed last Monday at $21.95.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.3% and a 44.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $57.00, which is a 163.8% upside from current levels. In a report released today, Needham also assigned a Buy rating to the stock with a $50.00 price target.
Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $34.9 million. In comparison, last year the company had a GAAP net loss of $32.96 million.
Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.